Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema . The trial met its primary endpoint of reduction in...

Related Keywords

,Drug Administration ,Ionis Pharmaceuticals Inc ,European Medicines Agency ,Ionis Pharmaceuticals ,New Drug Application ,Marketing Authorization Application ,European Medicines ,Orphan Drug Designation ,Markets ,